Jean-Luc Hoepffner is an expert in Urology at IRM Saint Augustin (France). Jean-Luc Hoepffner has authored 42 publications, the most recent in 2025, and is an investigator in 2 clinical trials. SLR score: 105 (community average: 125). How the SLR is computed.

LeadR Profile

Jean-Luc Hoepffner IRM Saint Augustin France
105 ScienceLeadR Reputation 105
Network Map

Urology

Subspecialties: Radiotherapy - Oncology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2014 - 2025

Source: PubMed

IRM Saint Augustin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 42

Citations

Citations: 594 1st author: 5 Last author: 3 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30).
PMID 41380977 — radiotherapy, urinary bladder, urinary bladder neoplasms, margins of excision, safety, neoplasms, radiotherapy, adjuvant, cystectomy, therapeutics
Radiother Oncol20250
Enhanced recovery after surgery protocol does not reduce the length of postoperative hospitalization after robot-assisted radical prostatectomy. Outcomes from the first randomized controlled trial: the (PROSTA-RAAC) study.
PMID 41240114 — urology, hospitalization, prostate, recycling, enhanced recovery after surgery, prostatectomy
World J Urol20250
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
PMID 39299443 — urinary bladder, urinary bladder neoplasms, neoplasms, drug therapy, biomarkers, cystectomy, therapeutics, tissues, prognosis, chemotherapy
Ann Oncol Top journal20243
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
PMID 38142702 — urinary bladder, urinary bladder neoplasms, muscles, progression-free survival, incidence, doxorubicin, neoplasms, cause of death, drug therapy, vinblastine, therapeutics, methotrexate, chemotherapy
Lancet Oncol Top journal202377
Outcomes of lateral approach in robot-assisted radical prostatectomy: insights from a single-surgeon experience.
PMID 38217830 — prostate, minimally invasive surgical procedures, prostatic neoplasms, prostatectomy, margins of excision, surgeons
J Robot Surg20241

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 3 1

By status:

Completed 2

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map